| 6-K |
Report
|
FORM 6-K |
Feb 18, 2025 |
Feb 18, 2025 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Feb 18, 2025 |
Feb 18, 2025 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Feb 18, 2025 |
Feb 18, 2025 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Feb 18, 2025 |
Feb 18, 2025 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 6, 2025 |
Feb 6, 2025 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 3, 2025 |
Feb 3, 2025 |
| 6-K |
Report
|
IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC |
Feb 3, 2025 |
Feb 3, 2025 |
| 6-K |
Report
|
ENHERTU APPROVED IN US FOR BREAST CANCER POST ET |
Jan 28, 2025 |
Jan 28, 2025 |
| 6-K |
Report
|
DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER |
Jan 21, 2025 |
Jan 21, 2025 |
| 6-K |
Report
|
CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL |
Jan 17, 2025 |
Jan 17, 2025 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2025 |
Jan 2, 2025 |
| 6-K |
Report
|
DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU |
Dec 26, 2024 |
Dec 26, 2024 |
| 6-K |
Report
|
TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL |
Dec 23, 2024 |
Dec 23, 2024 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Dec 16, 2024 |
Dec 16, 2024 |
| 6-K |
Report
|
IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC |
Dec 5, 2024 |
Dec 5, 2024 |
| 6-K |
Report
|
ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL |
Dec 4, 2024 |
Dec 4, 2024 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 2, 2024 |
Dec 2, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 2, 2024 |
Dec 2, 2024 |
| 6-K |
Report
|
TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER |
Nov 25, 2024 |
Nov 25, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 20, 2024 |
Nov 20, 2024 |
| 6-K |
Report
|
TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA |
Nov 18, 2024 |
Nov 18, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 15, 2024 |
Nov 15, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 15, 2024 |
Nov 15, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 13, 2024 |
Nov 13, 2024 |
| 6-K |
Report
|
ASTRAZENECA INVESTS $3.5 BILLION IN US |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
KOMET PHASE III TRIAL MET PRIMARY ENDPOINT |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
9M AND Q3 2024 RESULTS |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS |
Nov 8, 2024 |
Nov 8, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2024 |
Nov 1, 2024 |
| 6-K |
Report
|
AZN CHINA PRESIDENT UNDER INVESTIGATION |
Oct 30, 2024 |
Oct 30, 2024 |
| 6-K |
Report
|
FORM 6-K |
Oct 21, 2024 |
Oct 21, 2024 |
| 6-K |
Report
|
ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET |
Oct 7, 2024 |
Oct 7, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2024 |
Oct 1, 2024 |
| 6-K |
Report
|
TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER |
Sep 26, 2024 |
Sep 26, 2024 |
| 6-K |
Report
|
FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA |
Sep 23, 2024 |
Sep 23, 2024 |
| 6-K |
Report
|
FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 |
Sep 23, 2024 |
Sep 23, 2024 |
| 6-K |
Report
|
FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US |
Sep 20, 2024 |
Sep 20, 2024 |
| 6-K |
Report
|
FASENRA EGPA US FDA APPROVAL |
Sep 18, 2024 |
Sep 18, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 13, 2024 |
Sep 13, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 3, 2024 |
Sep 2, 2024 |
| 6-K |
Report
|
IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER |
Aug 16, 2024 |
Aug 16, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2024 |
Aug 1, 2024 |
| 6-K |
Report
|
ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING |
Jul 30, 2024 |
Jul 30, 2024 |
| 6-K |
Report
|
CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS |
Jul 29, 2024 |
Jul 29, 2024 |
| 6-K |
Report
|
ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER |
Jul 26, 2024 |
Jul 26, 2024 |
| 6-K |
Report
| Data |
FORM 6K |
Jul 25, 2024 |
Jun 30, 2024 |
| 6-K |
Report
|
ACQUISITION OF AMOLYT PHARMA COMPLETED |
Jul 15, 2024 |
Jul 15, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2024 |
Jul 1, 2024 |
| 6-K |
Report
|
LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL |
Jul 1, 2024 |
Jul 1, 2024 |
| 6-K |
Report
|
UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL |
Jun 25, 2024 |
Jun 25, 2024 |
| 6-K |
Report
|
IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER |
Jun 25, 2024 |
Jun 25, 2024 |
| 6-K |
Report
|
UPDATE ON CAPITELLO-290 PHASE III TRIAL |
Jun 18, 2024 |
Jun 18, 2024 |
| 6-K |
Report
|
IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER |
Jun 17, 2024 |
Jun 17, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 12, 2024 |
Jun 12, 2024 |
| 6-K |
Report
|
FORM 6-K |
Jun 4, 2024 |
Jun 4, 2024 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER |
May 28, 2024 |
May 28, 2024 |
| 6-K |
Report
|
ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 |
May 21, 2024 |
May 21, 2024 |
| 6-K |
Report
|
ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE |
May 20, 2024 |
May 20, 2024 |
| 6-K |
Report
|
SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT |
May 16, 2024 |
May 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 15, 2024 |
May 15, 2024 |
| 6-K |
Report
|
ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT |
May 7, 2024 |
May 7, 2024 |
| 6-K |
Report
|
CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL |
May 2, 2024 |
May 2, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2024 |
May 1, 2024 |
| 6-K |
Report
|
TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL |
Apr 29, 2024 |
Apr 29, 2024 |
| 6-K |
Report
|
ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW |
Apr 29, 2024 |
Apr 29, 2024 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 25, 2024 |
Apr 25, 2024 |
| 6-K |
Report
|
RESULT OF AGM |
Apr 11, 2024 |
Apr 11, 2024 |
| 6-K |
Report
|
ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% |
Apr 11, 2024 |
Apr 11, 2024 |
| 6-K |
Report
|
ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS |
Apr 8, 2024 |
Apr 8, 2024 |
| 6-K |
Report
|
IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC |
Apr 5, 2024 |
Apr 5, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 2, 2024 |
Apr 2, 2024 |
| 6-K |
Report
|
VOYDEYA APPROVED IN US |
Apr 2, 2024 |
Apr 2, 2024 |
| 6-K |
Report
|
FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER |
Apr 2, 2024 |
Apr 2, 2024 |
| 6-K |
Report
|
ULTOMIRIS APPROVED IN THE US FOR NMOSD |
Mar 25, 2024 |
Mar 25, 2024 |
| 6-K |
Report
|
FORM 6-K |
Mar 19, 2024 |
Mar 19, 2024 |
| 6-K |
Report
|
ASTRAZENECA TO ACQUIRE AMOLYT |
Mar 14, 2024 |
Mar 14, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 12, 2024 |
Mar 12, 2024 |
| 6-K |
Report
|
FORM 6-K |
Mar 7, 2024 |
Mar 7, 2024 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 7, 2024 |
Mar 7, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 6, 2024 |
Mar 6, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 6, 2024 |
Mar 6, 2024 |
| 6-K |
Report
|
EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC |
Mar 4, 2024 |
Mar 4, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2024 |
Mar 1, 2024 |
| 6-K |
Report
|
FORM 6-K |
Feb 26, 2024 |
Feb 26, 2024 |
| 6-K |
Report
|
VOYDEYA RECOMMENDED FOR EU APPROVAL |
Feb 26, 2024 |
Feb 26, 2024 |
| 6-K |
Report
|
ASTRAZENECA PRICES A $5BN BOND OFFERING |
Feb 22, 2024 |
Feb 22, 2024 |
| 6-K |
Report
|
FORM 6-K |
Feb 22, 2024 |
Feb 22, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 22, 2024 |
Feb 22, 2024 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Feb 21, 2024 |
Feb 21, 2024 |
| 6-K |
Report
|
FORM 6-K |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
FORM 6-K |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER |
Feb 20, 2024 |
Feb 19, 2024 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 8, 2024 |
Feb 8, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2024 |
Feb 1, 2024 |
| 6-K |
Report
|
FORM 6-K |
Jan 19, 2024 |
Jan 19, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2024 |
Jan 2, 2024 |
| 6-K |
Report
|
ASTRAZENECA ACQUIRES GRACELL |
Dec 27, 2023 |
Dec 27, 2023 |
| 6-K |
Report
|
FORM 6-K |
Dec 26, 2023 |
Dec 26, 2023 |
| 6-K |
Report
|
WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL |
Dec 22, 2023 |
Dec 22, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 14, 2023 |
Dec 14, 2023 |
| 6-K |
Report
|
FORM 6-K |
Dec 12, 2023 |
Dec 12, 2023 |
| 6-K |
Report
|
ASTRAZENECA TO ACQUIRE ICOSAVAX |
Dec 12, 2023 |
Dec 12, 2023 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 1, 2023 |
Dec 1, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2023 |
Dec 1, 2023 |
| 6-K |
Report
|
DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS |
Dec 1, 2023 |
Dec 1, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 24, 2023 |
Nov 24, 2023 |
| 6-K |
Report
|
TRUQAP APPROVED IN US FOR HR+ BREAST CANCER |
Nov 17, 2023 |
Nov 17, 2023 |
| 6-K |
Report
|
UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI |
Nov 14, 2023 |
Nov 14, 2023 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Nov 9, 2023 |
Nov 9, 2023 |
| 6-K |
Report
|
IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER |
Nov 9, 2023 |
Nov 9, 2023 |
| 6-K |
Report
|
AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA |
Nov 9, 2023 |
Nov 9, 2023 |
| 6-K |
Report
|
9M AND Q3 2023 RESULTS |
Nov 9, 2023 |
Nov 2, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2023 |
Nov 1, 2023 |
| 6-K |
Report
|
ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS |
Nov 1, 2023 |
Nov 1, 2023 |
| 6-K |
Report
|
ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS |
Oct 3, 2023 |
Oct 3, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 2, 2023 |
Oct 2, 2023 |
| 6-K |
Report
|
DATO-DXD IMPROVED PFS IN BREAST CANCER |
Sep 25, 2023 |
Sep 22, 2023 |
| 6-K |
Report
|
ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT |
Sep 20, 2023 |
Sep 20, 2023 |
| 6-K |
Report
|
ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC |
Sep 15, 2023 |
Sep 15, 2023 |
| 6-K |
Report
|
FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT |
Sep 11, 2023 |
Sep 11, 2023 |
| 6-K |
Report
|
UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD |
Sep 6, 2023 |
Sep 6, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2023 |
Sep 1, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2023 |
Aug 1, 2023 |
| 6-K |
Report
| Data |
FORM 6K |
Jul 28, 2023 |
Jun 30, 2023 |
| 6-K |
Report
|
ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER |
Jul 28, 2023 |
Jul 28, 2023 |
| 6-K |
Report
|
BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION |
Jul 17, 2023 |
Jul 17, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 3, 2023 |
Jul 3, 2023 |
| 6-K |
Report
|
DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER |
Jul 3, 2023 |
Jul 3, 2023 |
| 6-K |
Report
|
NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION |
Jun 9, 2023 |
Jun 9, 2023 |
| 6-K |
Report
|
ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS |
Jun 9, 2023 |
Jun 9, 2023 |
| 6-K |
Report
|
IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS |
Jun 2, 2023 |
Jun 2, 2023 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 1, 2023 |
Jun 1, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2023 |
Jun 1, 2023 |
| 6-K |
Report
|
LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER |
Jun 1, 2023 |
Jun 1, 2023 |
| 6-K |
Report
|
IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER |
May 26, 2023 |
May 26, 2023 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
May 22, 2023 |
May 22, 2023 |
| 6-K |
Report
|
TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER |
May 17, 2023 |
May 17, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 9, 2023 |
May 9, 2023 |
| 6-K |
Report
|
FARXIGA EXTENDED IN THE US FOR HEART FAILURE |
May 9, 2023 |
May 9, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 2, 2023 |
May 2, 2023 |
| 6-K |
Report
|
ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER |
May 2, 2023 |
May 2, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 2, 2023 |
May 2, 2023 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 27, 2023 |
Apr 27, 2023 |
| 6-K |
Report
|
RESULT OF AGM |
Apr 27, 2023 |
Apr 27, 2023 |
| 6-K |
Report
|
FORM 6-K |
Apr 27, 2023 |
Apr 27, 2023 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Apr 27, 2023 |
Apr 27, 2023 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Apr 26, 2023 |
Apr 26, 2023 |
| 6-K |
Report
|
UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI |
Apr 11, 2023 |
Apr 11, 2023 |
| 6-K |
Report
|
LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER |
Apr 5, 2023 |
Apr 5, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 3, 2023 |
Apr 3, 2023 |
| 6-K |
Report
|
ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL |
Apr 3, 2023 |
Apr 3, 2023 |
| 6-K |
Report
|
ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 |
Mar 30, 2023 |
Mar 30, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 27, 2023 |
Mar 27, 2023 |
| 6-K |
Report
|
FORM 6-K |
Mar 22, 2023 |
Mar 22, 2023 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 22, 2023 |
Mar 22, 2023 |
| 6-K |
Report
|
IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER |
Mar 9, 2023 |
Mar 9, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 8, 2023 |
Mar 8, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 8, 2023 |
Mar 8, 2023 |
| 6-K |
Report
|
ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS |
Mar 6, 2023 |
Mar 6, 2023 |
| 6-K |
Report
|
FORM 6-K |
Mar 3, 2023 |
Mar 3, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2023 |
Mar 1, 2023 |
| 6-K |
Report
|
ASTRAZENECA PRICES A $2.25BN BOND OFFERING |
Mar 1, 2023 |
Mar 1, 2023 |
| 6-K |
Report
|
ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING |
Feb 24, 2023 |
Feb 24, 2023 |
| 6-K |
Report
|
ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET |
Feb 24, 2023 |
Feb 24, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 24, 2023 |
Feb 24, 2023 |
| 6-K |
Report
|
ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 |
Feb 23, 2023 |
Feb 23, 2023 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Feb 22, 2023 |
Feb 22, 2023 |
| 6-K |
Report
|
FORM 6-K |
Feb 21, 2023 |
Feb 21, 2023 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Feb 21, 2023 |
Feb 21, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2023 |
Feb 13, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2023 |
Feb 13, 2023 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 9, 2023 |
Feb 9, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2023 |
Feb 1, 2023 |
| 6-K |
Report
|
UPDATE ON EVUSHELD US EUA |
Jan 26, 2023 |
Jan 26, 2023 |
| 6-K |
Report
|
ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED |
Jan 17, 2023 |
Jan 17, 2023 |
| 6-K |
Report
|
AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA |
Jan 11, 2023 |
Jan 11, 2023 |
| 6-K |
Report
|
ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET |
Jan 9, 2023 |
Jan 9, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 3, 2023 |
Jan 3, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 30, 2022 |
Dec 30, 2022 |
| 6-K |
Report
|
CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL |
Dec 28, 2022 |
Dec 28, 2022 |
| 6-K |
Report
|
IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS |
Dec 28, 2022 |
Dec 28, 2022 |
| 6-K |
Report
|
IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER |
Dec 21, 2022 |
Dec 21, 2022 |
| 6-K |
Report
|
LYNPARZA APPROVED IN EU FOR PROSTATE CANCER |
Dec 21, 2022 |
Dec 21, 2022 |
| 6-K |
Report
|
ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME |
Dec 19, 2022 |
Dec 19, 2022 |
| 6-K |
Report
|
ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD |
Dec 19, 2022 |
Dec 19, 2022 |
| 6-K |
Report
|
IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT |
Dec 19, 2022 |
Dec 19, 2022 |
| 6-K |
Report
|
UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL |
Dec 19, 2022 |
Dec 19, 2022 |
| 6-K |
Report
|
FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF |
Dec 19, 2022 |
Dec 19, 2022 |
| 6-K |
Report
|
UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA |
Dec 15, 2022 |
Dec 15, 2022 |
| 6-K |
Report
|
CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER |
Dec 8, 2022 |
Dec 8, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2022 |
Dec 1, 2022 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 1, 2022 |
Dec 1, 2022 |
| 6-K |
Report
|
ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE |
Nov 30, 2022 |
Nov 30, 2022 |
| 6-K |
Report
|
ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS |
Nov 29, 2022 |
Nov 29, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 23, 2022 |
Nov 23, 2022 |
| 6-K |
Report
|
ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC |
Nov 14, 2022 |
Nov 14, 2022 |
| 6-K |
Report
|
IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC |
Nov 14, 2022 |
Nov 14, 2022 |
| 6-K |
Report
|
LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC |
Nov 14, 2022 |
Nov 14, 2022 |
| 6-K |
Report
|
IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER |
Nov 14, 2022 |
Nov 11, 2022 |
| 6-K |
Report
|
YTD AND Q3 2022 RESULTS |
Nov 10, 2022 |
Nov 10, 2022 |
| 6-K |
Report
|
FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA |
Nov 9, 2022 |
Nov 9, 2022 |
| 6-K |
Report
|
BEYFORTUS (NIRSEVIMAB) APPROVED IN EU |
Nov 4, 2022 |
Nov 4, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2022 |
Nov 1, 2022 |
| 6-K |
Report
|
CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS |
Oct 26, 2022 |
Oct 26, 2022 |
| 6-K |
Report
|
UPDATE ON MESSINA PHASE III TRIAL |
Oct 25, 2022 |
Oct 25, 2022 |
| 6-K |
Report
|
IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER |
Oct 24, 2022 |
Oct 24, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 3, 2022 |
Oct 3, 2022 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Sep 30, 2022 |
Sep 30, 2022 |
| 6-K |
Report
|
KOSELUGO APPROVED IN JAPAN FOR NF1 |
Sep 27, 2022 |
Sep 27, 2022 |
| 6-K |
Report
|
TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA |
Sep 27, 2022 |
Sep 27, 2022 |
| 6-K |
Report
|
ULTOMIRIS APPROVED IN EU FOR GMG |
Sep 23, 2022 |
Sep 23, 2022 |
| 6-K |
Report
|
LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER |
Sep 22, 2022 |
Sep 22, 2022 |
| 6-K |
Report
|
TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA |
Sep 21, 2022 |
Sep 21, 2022 |
| 6-K |
Report
|
EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT |
Sep 20, 2022 |
Sep 20, 2022 |
| 6-K |
Report
|
DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT |
Sep 16, 2022 |
Sep 16, 2022 |
| 6-K |
Report
|
NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP |
Sep 16, 2022 |
Sep 16, 2022 |
| 6-K |
Report
|
EVUSHELD POSITIVE CHMP OPINION IN EU |
Sep 16, 2022 |
Sep 16, 2022 |
| 6-K |
Report
|
FORXIGA APPROVED IN CHINA FOR CKD |
Sep 6, 2022 |
Sep 6, 2022 |
| 6-K |
Report
|
IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER |
Sep 6, 2022 |
Sep 6, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2022 |
Sep 1, 2022 |
| 6-K |
Report
|
EVUSHELD APPROVED FOR COVID-19 IN JAPAN |
Aug 30, 2022 |
Aug 30, 2022 |
| 6-K |
Report
|
FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF |
Aug 30, 2022 |
Aug 30, 2022 |
| 6-K |
Report
|
FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE |
Aug 30, 2022 |
Aug 30, 2022 |
| 6-K |
Report
|
ULTOMIRIS APPROVED IN JAPAN FOR GMG |
Aug 25, 2022 |
Aug 25, 2022 |
| 6-K |
Report
|
TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER |
Aug 25, 2022 |
Aug 25, 2022 |
| 6-K |
Report
|
LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER |
Aug 25, 2022 |
Aug 25, 2022 |
| 6-K |
Report
|
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL |
Aug 16, 2022 |
Aug 16, 2022 |
| 6-K |
Report
|
ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 |
Aug 15, 2022 |
Aug 15, 2022 |
| 6-K |
Report
|
ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC |
Aug 12, 2022 |
Aug 12, 2022 |
| 6-K |
Report
|
ACQUISITION OF TENEOTWO COMPLETED |
Aug 11, 2022 |
Aug 11, 2022 |
| 6-K |
Report
|
ENHERTU APPROVED IN THE US FOR HER2-LOW MBC |
Aug 8, 2022 |
Aug 8, 2022 |
| 6-K |
Report
|
LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER |
Aug 4, 2022 |
Aug 4, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 1, 2022 |
Aug 1, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2022 |
Aug 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 1, 2022 |
Aug 1, 2022 |
| 6-K |
Report
| Data |
FORM 6-K |
Jul 29, 2022 |
Jun 30, 2022 |
| 6-K |
Report
|
CHAIR SUCCESSION |
Jul 29, 2022 |
Jul 29, 2022 |
| 6-K |
Report
|
TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA |
Jul 25, 2022 |
Jul 25, 2022 |
| 6-K |
Report
|
ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG |
Jul 25, 2022 |
Jul 25, 2022 |
| 6-K |
Report
|
ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC |
Jul 25, 2022 |
Jul 25, 2022 |
| 6-K |
Report
|
ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC |
Jul 19, 2022 |
Jul 19, 2022 |
| 6-K |
Report
|
ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER |
Jul 5, 2022 |
Jul 5, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2022 |
Jul 1, 2022 |
| 6-K |
Report
|
IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER |
Jun 30, 2022 |
Jun 30, 2022 |
| 6-K |
Report
|
ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL |
Jun 27, 2022 |
Jun 27, 2022 |
| 6-K |
Report
|
LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER |
Jun 27, 2022 |
Jun 27, 2022 |
| 6-K |
Report
|
EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS |
Jun 21, 2022 |
Jun 21, 2022 |
| 6-K |
Report
|
ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER |
Jun 6, 2022 |
Jun 6, 2022 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 1, 2022 |
Jun 1, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2022 |
Jun 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 20, 2022 |
May 20, 2022 |
| 6-K |
Report
|
APPOINTMENT OF JOINT CORPORATE BROKERS |
May 9, 2022 |
May 9, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 6, 2022 |
May 6, 2022 |
| 6-K |
Report
|
ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER |
May 5, 2022 |
May 5, 2022 |
| 6-K |
Report
|
FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT |
May 5, 2022 |
May 5, 2022 |
| 6-K |
Report
|
ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT |
May 5, 2022 |
May 5, 2022 |
| 6-K |
Report
|
IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC |
May 4, 2022 |
May 4, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 3, 2022 |
May 3, 2022 |
| 6-K |
Report
|
RESULT OF AGM |
Apr 29, 2022 |
Apr 29, 2022 |
| 6-K |
Report
|
ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS |
Apr 29, 2022 |
Apr 29, 2022 |
| 6-K |
Report
|
FIRST QUARTER 2022 RESULTS |
Apr 29, 2022 |
Apr 29, 2022 |
| 6-K |
Report
|
ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG |
Apr 28, 2022 |
Apr 28, 2022 |
| 6-K |
Report
|
ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER |
Apr 27, 2022 |
Apr 27, 2022 |
| 6-K |
Report
|
TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO |
Apr 25, 2022 |
Apr 25, 2022 |
| 6-K |
Report
|
ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC |
Apr 19, 2022 |
Apr 19, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2022 |
Apr 1, 2022 |
| 6-K |
Report
|
ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL |
Mar 29, 2022 |
Mar 29, 2022 |
| 6-K |
Report
|
EVUSHELD APPROVED IN THE EU FOR COVID-19 |
Mar 28, 2022 |
Mar 28, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 25, 2022 |
Mar 25, 2022 |
| 6-K |
Report
|
EVUSHELD POSITIVE EU CHMP OPINION |
Mar 24, 2022 |
Mar 24, 2022 |
| 6-K |
Report
|
UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA |
Mar 24, 2022 |
Mar 24, 2022 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 23, 2022 |
Mar 23, 2022 |
| 6-K |
Report
|
FORM 6-K |
Mar 23, 2022 |
Mar 23, 2022 |
| 6-K |
Report
|
SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS |
Mar 17, 2022 |
Mar 17, 2022 |
| 6-K |
Report
|
LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER |
Mar 14, 2022 |
Mar 14, 2022 |
| 6-K |
Report
|
UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS |
Mar 14, 2022 |
Mar 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 9, 2022 |
Mar 9, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 7, 2022 |
Mar 7, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Feb 23, 2022 |
Feb 23, 2022 |
| 6-K |
Report
|
CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT |
Feb 22, 2022 |
Feb 22, 2022 |
| 6-K |
Report
|
ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC |
Feb 22, 2022 |
Feb 22, 2022 |
| 6-K |
Report
|
SAPHNELO APPROVED IN EU FOR SLE |
Feb 16, 2022 |
Feb 16, 2022 |
| 6-K |
Report
|
LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE |
Feb 15, 2022 |
Feb 15, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 11, 2022 |
Feb 11, 2022 |
| 6-K |
Report
|
AZN: FULL YEAR AND Q4 2021 RESULTS |
Feb 10, 2022 |
Feb 10, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2022 |
Feb 1, 2022 |
| 6-K |
Report
|
IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER |
Jan 18, 2022 |
Jan 18, 2022 |
| 6-K |
Report
|
ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 |
Jan 7, 2022 |
Jan 7, 2022 |
| 6-K |
Report
|
TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED |
Jan 5, 2022 |
Jan 5, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 4, 2022 |
Jan 4, 2022 |
| 6-K |
Report
|
ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL |
Dec 29, 2021 |
Dec 29, 2021 |
| 6-K |
Report
|
ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG |
Dec 21, 2021 |
Dec 21, 2021 |
| 6-K |
Report
|
TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA |
Dec 20, 2021 |
Dec 20, 2021 |
| 6-K |
Report
|
SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE |
Dec 20, 2021 |
Dec 20, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 15, 2021 |
Dec 15, 2021 |
| 6-K |
Report
|
EVUSHELD US FDA EUA |
Dec 9, 2021 |
Dec 9, 2021 |
| 6-K |
Report
|
ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN |
Dec 7, 2021 |
Dec 7, 2021 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 1, 2021 |
Dec 1, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2021 |
Dec 1, 2021 |
| 6-K |
Report
|
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA |
Nov 30, 2021 |
Nov 30, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 15, 2021 |
Nov 15, 2021 |
| 6-K |
Report
|
AZN: YEAR TO DATE AND Q3 2021 RESULTS |
Nov 12, 2021 |
Nov 12, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2021 |
Nov 1, 2021 |
| 6-K |
Report
|
ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR |
Nov 1, 2021 |
Nov 1, 2021 |
| 6-K |
Report
|
IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER |
Oct 25, 2021 |
Oct 25, 2021 |
| 6-K |
Report
|
AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER |
Oct 18, 2021 |
Oct 18, 2021 |
| 6-K |
Report
|
IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER |
Oct 15, 2021 |
Oct 15, 2021 |
| 6-K |
Report
|
AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
ENHERTU GRANTED BTD FOR BREAST CANCER |
Oct 4, 2021 |
Oct 4, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2021 |
Oct 1, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 30, 2021 |
Sep 30, 2021 |
| 6-K |
Report
|
ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES |
Sep 29, 2021 |
Sep 29, 2021 |
| 6-K |
Report
|
SAPHNELO APPROVED IN JAPAN FOR SLE |
Sep 28, 2021 |
Sep 28, 2021 |
| 6-K |
Report
|
LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT |
Sep 24, 2021 |
Sep 24, 2021 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGE |
Sep 23, 2021 |
Sep 23, 2021 |
| 6-K |
Report
|
NEW SUSTAINABILITY COMMITTEE OF THE BOARD |
Sep 23, 2021 |
Sep 23, 2021 |
| 6-K |
Report
|
ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT |
Sep 21, 2021 |
Sep 21, 2021 |
| 6-K |
Report
|
ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% |
Sep 20, 2021 |
Sep 20, 2021 |
| 6-K |
Report
|
IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON |
Sep 9, 2021 |
Sep 9, 2021 |
| 6-K |
Report
|
FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC |
Sep 9, 2021 |
Sep 9, 2021 |
| 6-K |
Report
|
ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH |
Sep 3, 2021 |
Sep 3, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2021 |
Sep 1, 2021 |
| 6-K |
Report
|
FORXIGA APPROVED IN JAPAN FOR CKD |
Aug 26, 2021 |
Aug 26, 2021 |
| 6-K |
Report
|
ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT |
Aug 26, 2021 |
Aug 26, 2021 |
| 6-K |
Report
|
UPDATE ON ULTOMIRIS PHASE III ALS TRIAL |
Aug 20, 2021 |
Aug 20, 2021 |
| 6-K |
Report
|
AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT |
Aug 20, 2021 |
Aug 20, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 16, 2021 |
Aug 16, 2021 |
| 6-K |
Report
|
UPDATE ON US REVIEW OF ROXADUSTAT |
Aug 11, 2021 |
Aug 11, 2021 |
| 6-K |
Report
|
FORXIGA APPROVED IN THE EU FOR CKD |
Aug 9, 2021 |
Aug 9, 2021 |
| 6-K |
Report
|
ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT |
Aug 9, 2021 |
Aug 9, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 2, 2021 |
Aug 2, 2021 |
| 6-K |
Report
|
SAPHNELO APPROVED IN THE US FOR SLE |
Aug 2, 2021 |
Aug 2, 2021 |
| 6-K/A |
Report
| Data |
FORM 6-K/A |
Jul 30, 2021 |
Jun 30, 2021 |
| 6-K |
Report
| Data |
FORM 6-K |
Jul 30, 2021 |
Jun 30, 2021 |
| 6-K |
Report
|
ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH |
Jul 26, 2021 |
Jul 26, 2021 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Jul 22, 2021 |
Jul 22, 2021 |
| 6-K |
Report
|
FORM 6-K |
Jul 21, 2021 |
Jul 21, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 21, 2021 |
Jul 21, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 21, 2021 |
Jul 21, 2021 |
| 6-K |
Report
|
ACQUISITION OF ALEXION COMPLETED |
Jul 21, 2021 |
Jul 21, 2021 |
| 6-K |
Report
|
IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC |
Jul 19, 2021 |
Jul 19, 2021 |
| 6-K |
Report
|
STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT |
Jul 16, 2021 |
Jul 16, 2021 |
| 6-K |
Report
|
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK |
Jul 14, 2021 |
Jul 14, 2021 |
| 6-K |
Report
|
TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA |
Jul 8, 2021 |
Jul 8, 2021 |
| 6-K |
Report
|
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU |
Jul 6, 2021 |
Jul 6, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2021 |
Jul 1, 2021 |
| 6-K |
Report
|
FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD |
Jun 28, 2021 |
Jun 28, 2021 |
| 6-K |
Report
|
NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE |
Jun 28, 2021 |
Jun 28, 2021 |
| 6-K |
Report
|
LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER |
Jun 24, 2021 |
Jun 24, 2021 |
| 6-K |
Report
|
ORPATHYS APPROVED IN CHINA FOR LUNG CANCER |
Jun 23, 2021 |
Jun 23, 2021 |
| 6-K |
Report
|
KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 |
Jun 22, 2021 |
Jun 22, 2021 |
| 6-K |
Report
|
UPDATE ON AZD7442 STORM CHASER TRIAL |
Jun 15, 2021 |
Jun 15, 2021 |
| 6-K |
Report
|
CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB |
Jun 7, 2021 |
Jun 7, 2021 |
| 6-K |
Report
|
LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER |
Jun 4, 2021 |
Jun 4, 2021 |
| 6-K |
Report
|
ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER |
Jun 4, 2021 |
Jun 4, 2021 |
| 6-K |
Report
|
PUBLICATION OF FINAL TERMS |
Jun 2, 2021 |
Jun 2, 2021 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 1, 2021 |
Jun 1, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2021 |
Jun 1, 2021 |
| 6-K |
Report
|
FORM 6-K |
May 28, 2021 |
May 28, 2021 |
| 6-K |
Report
|
TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG |
May 28, 2021 |
May 28, 2021 |
| 6-K |
Report
|
ASTRAZENECA PRICES A EUR800M BOND OFFERING |
May 27, 2021 |
May 27, 2021 |
| 6-K |
Report
|
ASTRAZENECA PRICES A $7BN BOND OFFERING |
May 26, 2021 |
May 26, 2021 |
| 6-K |
Report
|
FORM 6-K |
May 26, 2021 |
May 26, 2021 |
| 6-K |
Report
|
EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS |
May 25, 2021 |
May 25, 2021 |
| 6-K |
Report
|
FORM 6-K |
May 24, 2021 |
May 24, 2021 |
| 6-K |
Report
|
ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN |
May 21, 2021 |
May 21, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 18, 2021 |
May 18, 2021 |
| 6-K |
Report
|
RESULT OF AGM |
May 11, 2021 |
May 11, 2021 |
| 6-K |
Report
|
SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION |
May 11, 2021 |
May 11, 2021 |
| 6-K |
Report
|
IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON |
May 7, 2021 |
May 7, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 4, 2021 |
May 4, 2021 |
| 6-K |
Report
|
FARXIGA APPROVED IN THE US FOR CKD |
May 4, 2021 |
May 4, 2021 |
| 6-K |
Report
|
AZN: FIRST QUARTER 2021 RESULTS |
Apr 30, 2021 |
Apr 30, 2021 |
| 6-K |
Report
|
NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
Apr 26, 2021 |
Apr 26, 2021 |
| 6-K |
Report
|
TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION |
Apr 26, 2021 |
Apr 26, 2021 |
| 6-K |
Report
|
SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 |
Apr 26, 2021 |
Apr 26, 2021 |
| 6-K |
Report
|
US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION |
Apr 16, 2021 |
Apr 16, 2021 |
| 6-K |
Report
|
TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER |
Apr 14, 2021 |
Apr 14, 2021 |
| 6-K |
Report
|
FORM 6-K |
Apr 12, 2021 |
Apr 12, 2021 |
| 6-K |
Report
|
CIRCULAR AND NOTICE OF GENERAL MEETING |
Apr 12, 2021 |
Apr 12, 2021 |
| 6-K |
Report
|
UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL |
Apr 12, 2021 |
Apr 12, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2021 |
Apr 1, 2021 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 30, 2021 |
Mar 30, 2021 |
| 6-K |
Report
|
FORM 6-K |
Mar 30, 2021 |
Mar 30, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 25, 2021 |
Mar 25, 2021 |
| 6-K |
Report
|
AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY |
Mar 25, 2021 |
Mar 25, 2021 |
| 6-K |
Report
|
ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT |
Mar 22, 2021 |
Mar 22, 2021 |
| 6-K |
Report
|
DIVESTMENT OF VIELA SHAREHOLDING COMPLETED |
Mar 16, 2021 |
Mar 16, 2021 |
| 6-K |
Report
|
US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES |
Mar 16, 2021 |
Mar 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 9, 2021 |
Mar 9, 2021 |
| 6-K |
Report
|
DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES |
Mar 4, 2021 |
Mar 4, 2021 |
| 6-K |
Report
|
US COURT DECISION FAVOURS SYMBICORT PATENTS |
Mar 3, 2021 |
Mar 3, 2021 |
| 6-K |
Report
|
FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE |
Mar 2, 2021 |
Mar 2, 2021 |
| 6-K |
Report
|
TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL |
Mar 1, 2021 |
Mar 1, 2021 |
| 6-K |
Report
|
VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US |
Feb 22, 2021 |
Feb 22, 2021 |
| 6-K |
Report
|
LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA |
Feb 17, 2021 |
Feb 17, 2021 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Feb 16, 2021 |
Feb 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 16, 2021 |
Feb 16, 2021 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Feb 16, 2021 |
Feb 16, 2021 |
| 6-K |
Report
|
ASTRAZENECA NON-EXECUTIVE BOARD CHANGES |
Feb 11, 2021 |
Feb 11, 2021 |
| 6-K |
Report
|
AZN: FULL-YEAR 2020 RESULTS |
Feb 11, 2021 |
Feb 11, 2021 |
| 6-K |
Report
|
DIVESTMENT OF CRESTOR IN EUROPE COMPLETED |
Feb 10, 2021 |
Feb 10, 2021 |
| 6-K |
Report
|
UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI |
Feb 5, 2021 |
Feb 5, 2021 |
| 6-K |
Report
|
FORXIGA APPROVED IN CHINA FOR HEART FAILURE |
Feb 4, 2021 |
Feb 4, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2021 |
Feb 1, 2021 |
| 6-K |
Report
|
ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING |
Feb 1, 2021 |
Feb 1, 2021 |
| 6-K |
Report
|
COVID-19 VACCINE AUTHORISED FOR USE BY THE EU |
Feb 1, 2021 |
Feb 1, 2021 |
| 6-K |
Report
|
COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU |
Jan 29, 2021 |
Jan 29, 2021 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Jan 26, 2021 |
Jan 26, 2021 |
| 6-K |
Report
|
SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA |
Jan 26, 2021 |
Jan 26, 2021 |
| 6-K |
Report
|
CALQUENCE APPROVED IN JAPAN FOR CLL |
Jan 25, 2021 |
Jan 25, 2021 |
| 6-K |
Report
|
CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB |
Jan 25, 2021 |
Jan 25, 2021 |
| 6-K |
Report
|
ENHERTU APPROVED IN THE EU FOR BREAST CANCER |
Jan 20, 2021 |
Jan 20, 2021 |
| 6-K |
Report
|
ENHERTU APPROVED IN THE US FOR GASTRIC CANCER |
Jan 19, 2021 |
Jan 19, 2021 |
| 6-K |
Report
|
IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO |
Jan 15, 2021 |
Jan 15, 2021 |
| 6-K |
Report
|
FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR |
Jan 6, 2021 |
Jan 6, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 4, 2021 |
Jan 4, 2021 |
| 6-K |
Report
|
ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED |
Jan 4, 2021 |
Jan 4, 2021 |
| 6-K |
Report
|
ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK |
Dec 30, 2020 |
Dec 30, 2020 |
| 6-K |
Report
|
LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P |
Dec 29, 2020 |
Dec 29, 2020 |
| 6-K |
Report
|
TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST |
Dec 21, 2020 |
Dec 21, 2020 |
| 6-K |
Report
|
UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS |
Dec 21, 2020 |
Dec 21, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 17, 2020 |
Dec 17, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 16, 2020 |
Dec 16, 2020 |
| 6-K |
Report
|
IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION |
Dec 15, 2020 |
Dec 15, 2020 |
| 6-K |
Report
|
TRASTUZUMAB DERUXTECAN POSITIVE CHMP |
Dec 14, 2020 |
Dec 14, 2020 |
| 6-K |
Report
|
TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD |
Dec 14, 2020 |
Dec 14, 2020 |
| 6-K |
Report
|
ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC |
Dec 14, 2020 |
Dec 14, 2020 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 1, 2020 |
Dec 1, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2020 |
Dec 1, 2020 |
| 6-K |
Report
|
CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE |
Dec 1, 2020 |
Dec 1, 2020 |
| 6-K |
Report
|
FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE |
Nov 30, 2020 |
Nov 30, 2020 |
| 6-K |
Report
|
AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 |
Nov 23, 2020 |
Nov 23, 2020 |
| 6-K |
Report
|
IMFINZI NEW DOSING APPROVED IN THE US |
Nov 20, 2020 |
Nov 20, 2020 |
| 6-K |
Report
|
TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
Nov 10, 2020 |
Nov 10, 2020 |
| 6-K |
Report
|
CALQUENCE APPROVED IN THE EU FOR CLL |
Nov 9, 2020 |
Nov 9, 2020 |
| 6-K |
Report
|
BRILINTA APPROVED IN THE US IN STROKE |
Nov 6, 2020 |
Nov 6, 2020 |
| 6-K |
Report
|
AZN: YEAR-TO-DATE AND Q3 2020 RESULTS |
Nov 5, 2020 |
Nov 5, 2020 |
| 6-K |
Report
|
FORXIGA APPROVED IN THE EU FOR HEART FAILURE |
Nov 5, 2020 |
Nov 5, 2020 |
| 6-K |
Report
|
LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
Nov 5, 2020 |
Nov 5, 2020 |
| 6-K |
Report
|
LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT |
Nov 5, 2020 |
Nov 5, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 2, 2020 |
Nov 2, 2020 |
| 6-K |
Report
|
ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES |
Oct 30, 2020 |
Oct 30, 2020 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Oct 29, 2020 |
Oct 29, 2020 |
| 6-K |
Report
|
ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET |
Oct 28, 2020 |
Oct 28, 2020 |
| 6-K |
Report
|
FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA |
Oct 28, 2020 |
Oct 28, 2020 |
| 6-K |
Report
|
TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW |
Oct 20, 2020 |
Oct 20, 2020 |
| 6-K |
Report
|
FORXIGA HF RECEIVES POSITIVE CHMP OPINION |
Oct 19, 2020 |
Oct 19, 2020 |
| 6-K |
Report
|
TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION |
Oct 19, 2020 |
Oct 19, 2020 |
| 6-K |
Report
|
COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE |
Oct 2, 2020 |
Oct 2, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2020 |
Oct 1, 2020 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Sep 25, 2020 |
Sep 25, 2020 |
| 6-K |
Report
|
LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC |
Sep 21, 2020 |
Sep 21, 2020 |
| 6-K |
Report
|
LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT |
Sep 21, 2020 |
Sep 21, 2020 |
| 6-K |
Report
|
TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV |
Sep 21, 2020 |
Sep 21, 2020 |
| 6-K |
Report
|
ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ |
Sep 10, 2020 |
Sep 10, 2020 |
| 6-K |
Report
|
FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I |
Sep 10, 2020 |
Sep 10, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2020 |
Sep 1, 2020 |
| 6-K |
Report
|
IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER |
Sep 1, 2020 |
Sep 1, 2020 |
| 6-K |
Report
|
FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH |
Sep 1, 2020 |
Sep 1, 2020 |
| 6-K |
Report
|
PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE |
Aug 25, 2020 |
Aug 25, 2020 |
| 6-K |
Report
|
IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C |
Aug 21, 2020 |
Aug 21, 2020 |
| 6-K |
Report
|
IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE |
Aug 18, 2020 |
Aug 18, 2020 |
| 6-K |
Report
|
FORM 6-K |
Aug 6, 2020 |
Aug 6, 2020 |
| 6-K |
Report
|
ASTRAZENECA PRICES A $3BN BOND ISSUE |
Aug 4, 2020 |
Aug 4, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 3, 2020 |
Aug 3, 2020 |
| 6-K/A |
Report
| Data |
6-K/A |
Jul 31, 2020 |
Jun 30, 2020 |
| 6-K |
Report
|
AZN: H1 2020 RESULTS |
Jul 30, 2020 |
Jul 30, 2020 |
| 6-K |
Report
|
TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER |
Jul 30, 2020 |
Jul 30, 2020 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Jul 29, 2020 |
Jul 29, 2020 |
| 6-K |
Report
|
FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS |
Jul 28, 2020 |
Jul 28, 2020 |
| 6-K |
Report
|
IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC |
Jul 27, 2020 |
Jul 27, 2020 |
| 6-K |
Report
|
CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL |
Jul 27, 2020 |
Jul 27, 2020 |
| 6-K |
Report
|
ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY |
Jul 27, 2020 |
Jul 27, 2020 |
| 6-K |
Report
|
BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD |
Jul 24, 2020 |
Jul 24, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 22, 2020 |
Jul 22, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 22, 2020 |
Jul 22, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 21, 2020 |
Jul 21, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 21, 2020 |
Jul 21, 2020 |
| 6-K |
Report
|
COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P |
Jul 20, 2020 |
Jul 20, 2020 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Jul 16, 2020 |
Jul 16, 2020 |
| 6-K |
Report
|
BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE |
Jul 9, 2020 |
Jul 9, 2020 |
| 6-K |
Report
|
LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER |
Jul 8, 2020 |
Jul 8, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2020 |
Jul 1, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 30, 2020 |
Jun 30, 2020 |
| 6-K |
Report
|
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE |
Jun 30, 2020 |
Jun 30, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jun 17, 2020 |
Jun 17, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jun 17, 2020 |
Jun 17, 2020 |
| 6-K |
Report
|
ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S |
Jun 15, 2020 |
Jun 15, 2020 |
| 6-K |
Report
|
EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS |
Jun 11, 2020 |
Jun 11, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2020 |
Jun 1, 2020 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 1, 2020 |
Jun 1, 2020 |
| 6-K |
Report
|
LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC |
Jun 1, 2020 |
Jun 1, 2020 |
| 6-K |
Report
|
BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE |
Jun 1, 2020 |
Jun 1, 2020 |
| 6-K |
Report
|
ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- |
May 29, 2020 |
May 29, 2020 |
| 6-K |
Report
|
IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE |
May 29, 2020 |
May 29, 2020 |
| 6-K |
Report
|
TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM |
May 29, 2020 |
May 29, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 26, 2020 |
May 26, 2020 |
| 6-K |
Report
|
ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER |
May 22, 2020 |
May 22, 2020 |
| 6-K |
Report
|
ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST |
May 21, 2020 |
May 21, 2020 |
| 6-K |
Report
|
LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT |
May 20, 2020 |
May 20, 2020 |
| 6-K |
Report
|
ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER |
May 18, 2020 |
May 18, 2020 |
| 6-K |
Report
|
BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD |
May 18, 2020 |
May 18, 2020 |
| 6-K |
Report
|
ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET |
May 11, 2020 |
May 11, 2020 |
| 6-K |
Report
|
ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM |
May 11, 2020 |
May 11, 2020 |
| 6-K |
Report
|
LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
May 11, 2020 |
May 11, 2020 |
| 6-K |
Report
|
FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H |
May 6, 2020 |
May 6, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2020 |
May 1, 2020 |
| 6-K |
Report
|
RESULT OF AGM |
Apr 29, 2020 |
Apr 29, 2020 |
| 6-K |
Report
|
AZN: FIRST-QUARTER 2020 RESULTS |
Apr 29, 2020 |
Apr 29, 2020 |
| 6-K |
Report
|
LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B |
Apr 24, 2020 |
Apr 24, 2020 |
| 6-K |
Report
|
CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING |
Apr 17, 2020 |
Apr 17, 2020 |
| 6-K |
Report
|
KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED |
Apr 2, 2020 |
Apr 2, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2020 |
Apr 1, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 31, 2020 |
Mar 31, 2020 |
| 6-K |
Report
|
FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA |
Mar 30, 2020 |
Mar 30, 2020 |
| 6-K |
Report
|
IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Mar 30, 2020 |
Mar 30, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 26, 2020 |
Mar 26, 2020 |
| 6-K |
Report
|
LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA |
Mar 26, 2020 |
Mar 26, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 20, 2020 |
Mar 20, 2020 |
| 6-K |
Report
|
LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA |
Mar 19, 2020 |
Mar 19, 2020 |
| 6-K |
Report
|
IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE |
Mar 17, 2020 |
Mar 17, 2020 |
| 6-K |
Report
|
6-K |
Mar 12, 2020 |
Mar 12, 2020 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 12, 2020 |
Mar 12, 2020 |
| 6-K |
Report
|
UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS |
Mar 12, 2020 |
Mar 12, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 10, 2020 |
Mar 10, 2020 |
| 6-K |
Report
|
UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S |
Mar 6, 2020 |
Mar 6, 2020 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Mar 4, 2020 |
Mar 4, 2020 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Mar 3, 2020 |
Mar 3, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 2, 2020 |
Mar 2, 2020 |
| 6-K |
Report
|
ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY |
Mar 2, 2020 |
Mar 2, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 27, 2020 |
Feb 27, 2020 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK |
Feb 25, 2020 |
Feb 25, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| 6-K |
Report
|
AZN: FULL-YEAR AND Q4 2019 RESULTS |
Feb 14, 2020 |
Feb 14, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 3, 2020 |
Feb 3, 2020 |
| 6-K |
Report
|
PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP |
Jan 27, 2020 |
Jan 27, 2020 |
| 6-K |
Report
|
ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN |
Jan 27, 2020 |
Jan 27, 2020 |
| 6-K |
Report
|
BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE |
Jan 27, 2020 |
Jan 27, 2020 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES |
Jan 27, 2020 |
Jan 27, 2020 |
| 6-K |
Report
|
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED |
Jan 21, 2020 |
Jan 20, 2020 |
| 6-K |
Report
|
IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN |
Jan 21, 2020 |
Jan 20, 2020 |
| 6-K |
Report
|
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA |
Jan 6, 2020 |
Jan 6, 2020 |
| 6-K |
Report
|
FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED |
Jan 6, 2020 |
Jan 6, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2020 |
Jan 2, 2020 |
| 6-K |
Report
|
LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- |
Dec 30, 2019 |
Dec 30, 2019 |
| 6-K |
Report
|
ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP |
Dec 23, 2019 |
Dec 23, 2019 |
| 6-K |
Report
|
ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB |
Dec 23, 2019 |
Dec 23, 2019 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO |
Dec 20, 2019 |
Dec 20, 2019 |
| 6-K |
Report
|
FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER |
Dec 17, 2019 |
Dec 17, 2019 |
| 6-K |
Report
|
SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA |
Dec 16, 2019 |
Dec 16, 2019 |
| 6-K |
Report
|
IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL |
Dec 12, 2019 |
Dec 12, 2019 |
| 6-K |
Report
|
TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE |
Dec 11, 2019 |
Dec 11, 2019 |
| 6-K |
Report
|
LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV |
Dec 5, 2019 |
Dec 5, 2019 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA |
Dec 3, 2019 |
Dec 3, 2019 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 2, 2019 |
Dec 2, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 2, 2019 |
Dec 2, 2019 |
| 6-K |
Report
|
IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE |
Nov 29, 2019 |
Nov 29, 2019 |
| 6-K |
Report
|
CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM |
Nov 21, 2019 |
Nov 21, 2019 |
| 6-K |
Report
|
QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D |
Nov 15, 2019 |
Nov 15, 2019 |
| 6-K |
Report
|
FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB |
Nov 14, 2019 |
Nov 14, 2019 |
| 6-K |
Report
|
ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE |
Nov 12, 2019 |
Nov 12, 2019 |
| 6-K |
Report
|
ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I |
Nov 12, 2019 |
Nov 12, 2019 |
| 6-K |
Report
|
ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE |
Nov 8, 2019 |
Nov 8, 2019 |
| 6-K |
Report
|
CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN |
Nov 6, 2019 |
Nov 6, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2019 |
Nov 1, 2019 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA |
Oct 30, 2019 |
Oct 30, 2019 |
| 6-K |
Report
|
IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED |
Oct 28, 2019 |
Oct 28, 2019 |
| 6-K |
Report
|
ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS |
Oct 24, 2019 |
Oct 24, 2019 |
| 6-K |
Report
|
FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU |
Oct 21, 2019 |
Oct 21, 2019 |
| 6-K |
Report
|
TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT |
Oct 17, 2019 |
Oct 17, 2019 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Oct 4, 2019 |
Oct 4, 2019 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Oct 4, 2019 |
Oct 4, 2019 |
| 6-K |
Report
|
FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION |
Oct 4, 2019 |
Oct 4, 2019 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Oct 3, 2019 |
Oct 3, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2019 |
Oct 1, 2019 |
| 6-K |
Report
|
ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR |
Oct 1, 2019 |
Oct 1, 2019 |
| 6-K |
Report
|
UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD |
Oct 1, 2019 |
Oct 1, 2019 |
| 6-K |
Report
|
LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN |
Sep 30, 2019 |
Sep 30, 2019 |
| 6-K |
Report
|
LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS |
Sep 30, 2019 |
Sep 30, 2019 |
| 6-K |
Report
|
TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN |
Sep 30, 2019 |
Sep 30, 2019 |
| 6-K |
Report
|
QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP |
Sep 23, 2019 |
Sep 23, 2019 |
| 6-K |
Report
|
ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA |
Sep 18, 2019 |
Sep 18, 2019 |
| 6-K |
Report
|
IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP |
Sep 9, 2019 |
Sep 9, 2019 |
| 6-K |
Report
|
TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE |
Sep 4, 2019 |
Sep 4, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 3, 2019 |
Sep 3, 2019 |
| 6-K |
Report
|
DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC |
Sep 3, 2019 |
Sep 3, 2019 |
| 6-K |
Report
|
BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART |
Sep 3, 2019 |
Sep 3, 2019 |
| 6-K |
Report
|
ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS |
Aug 29, 2019 |
Aug 29, 2019 |
| 6-K |
Report
|
BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS |
Aug 28, 2019 |
Aug 28, 2019 |
| 6-K |
Report
|
FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS |
Aug 28, 2019 |
Aug 28, 2019 |
| 6-K |
Report
|
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND |
Aug 22, 2019 |
Aug 22, 2019 |
| 6-K |
Report
|
ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW |
Aug 22, 2019 |
Aug 22, 2019 |
| 6-K |
Report
|
UPDATE ON THE PHASE III NEPTUNE TRIAL |
Aug 21, 2019 |
Aug 21, 2019 |
| 6-K |
Report
|
FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III |
Aug 20, 2019 |
Aug 20, 2019 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Aug 19, 2019 |
Aug 19, 2019 |
| 6-K |
Report
|
CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION |
Aug 14, 2019 |
Aug 14, 2019 |
| 6-K |
Report
|
LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT |
Aug 14, 2019 |
Aug 14, 2019 |
| 6-K |
Report
|
TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL |
Aug 9, 2019 |
Aug 9, 2019 |
| 6-K |
Report
|
LYNPARZA PHASE III PROFOUND TRIAL IN HRR* |
Aug 7, 2019 |
Aug 7, 2019 |
| 6-K |
Report
|
FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES |
Aug 5, 2019 |
Aug 5, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2019 |
Aug 1, 2019 |
| 6-K |
Report
| Data |
6-K |
Jul 25, 2019 |
Jun 30, 2019 |
| 6-K |
Report
|
UPDATE ON US REGULATORY DECISION FOR FARXIGA |
Jul 15, 2019 |
Jul 15, 2019 |
| 6-K |
Report
|
IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER |
Jul 12, 2019 |
Jul 12, 2019 |
| 6-K |
Report
|
FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF |
Jul 1, 2019 |
Jul 1, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2019 |
Jul 1, 2019 |
| 6-K |
Report
|
FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR |
Jul 1, 2019 |
Jul 1, 2019 |
| 6-K |
Report
|
IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM |
Jun 27, 2019 |
Jun 27, 2019 |
| 6-K |
Report
|
BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI |
Jun 19, 2019 |
Jun 19, 2019 |
| 6-K |
Report
|
LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA |
Jun 19, 2019 |
Jun 19, 2019 |
| 6-K |
Report
|
BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA |
Jun 19, 2019 |
Jun 19, 2019 |
| 6-K |
Report
|
LYNPARZA APPROVED IN THE EU FOR 1ST-LINE |
Jun 18, 2019 |
Jun 18, 2019 |
| 6-K |
Report
|
CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT |
Jun 17, 2019 |
Jun 17, 2019 |
| 6-K |
Report
|
PUBLICATION OF A PROSPECTUS |
Jun 12, 2019 |
Jun 12, 2019 |
| 6-K |
Report
|
CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY |
Jun 6, 2019 |
Jun 6, 2019 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 3, 2019 |
Jun 3, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 3, 2019 |
Jun 3, 2019 |
| 6-K |
Report
|
LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM |
Jun 3, 2019 |
Jun 3, 2019 |
| 6-K |
Report
|
POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III |
May 10, 2019 |
May 10, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 8, 2019 |
May 8, 2019 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
May 8, 2019 |
May 8, 2019 |
| 6-K |
Report
|
TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY |
May 8, 2019 |
May 8, 2019 |
| 6-K |
Report
|
CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT |
May 7, 2019 |
May 7, 2019 |
| 6-K |
Report
|
QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES |
May 3, 2019 |
May 3, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2019 |
May 1, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 1, 2019 |
May 1, 2019 |
| 6-K |
Report
|
LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST |
Apr 29, 2019 |
Apr 29, 2019 |
| 6-K |
Report
|
RESULT OF AGM |
Apr 26, 2019 |
Apr 26, 2019 |
| 6-K |
Report
|
AZN: Q1 2019 RESULTS |
Apr 26, 2019 |
Apr 26, 2019 |
| 6-K |
Report
|
LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE |
Apr 10, 2019 |
Apr 10, 2019 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Apr 4, 2019 |
Apr 4, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 3, 2019 |
Apr 3, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 2, 2019 |
Apr 2, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2019 |
Apr 1, 2019 |
| 6-K |
Report
|
SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION |
Apr 1, 2019 |
Apr 1, 2019 |
| 6-K |
Report
|
RESULTS OF PLACING |
Mar 29, 2019 |
Mar 29, 2019 |
| 6-K |
Report
|
AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL |
Mar 29, 2019 |
Mar 29, 2019 |
| 6-K |
Report
|
FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES |
Mar 27, 2019 |
Mar 27, 2019 |
| 6-K |
Report
|
FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES |
Mar 25, 2019 |
Mar 25, 2019 |
| 6-K |
Report
|
US FDA GRANTS SARACATINIB ODD FOR IPF |
Mar 18, 2019 |
Mar 18, 2019 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 14, 2019 |
Mar 14, 2019 |
| 6-K |
Report
|
6-K |
Mar 14, 2019 |
Mar 14, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 12, 2019 |
Mar 12, 2019 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Mar 6, 2019 |
Mar 6, 2019 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Mar 5, 2019 |
Mar 5, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2019 |
Mar 1, 2019 |
| 6-K |
Report
|
LYNPARZA RECEIVES POSITIVE EU CHMP OPINION |
Mar 1, 2019 |
Mar 1, 2019 |
| 6-K |
Report
|
LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION |
Feb 26, 2019 |
Feb 26, 2019 |
| 6-K |
Report
|
BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT |
Feb 25, 2019 |
Feb 25, 2019 |
| 6-K |
Report
|
ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS |
Feb 14, 2019 |
Feb 14, 2019 |
| 6-K |
Report
|
US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION |
Feb 6, 2019 |
Feb 6, 2019 |
| 6-K |
Report
|
US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION |
Feb 5, 2019 |
Feb 5, 2019 |
| 6-K |
Report
|
EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 |
Feb 5, 2019 |
Feb 5, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2019 |
Feb 1, 2019 |
| 6-K |
Report
|
FORXIGA RECEIVES POSITIVE EU CHMP OPINION |
Feb 1, 2019 |
Feb 1, 2019 |
| 6-K |
Report
|
COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS |
Jan 25, 2019 |
Jan 25, 2019 |
| 6-K |
Report
|
ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES |
Jan 7, 2019 |
Jan 7, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2019 |
Jan 2, 2019 |
| 6-K |
Report
|
BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD |
Dec 20, 2018 |
Dec 20, 2018 |
| 6-K |
Report
|
LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL |
Dec 20, 2018 |
Dec 20, 2018 |
| 6-K |
Report
|
PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS |
Dec 20, 2018 |
Dec 20, 2018 |
| 6-K |
Report
|
FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY |
Dec 19, 2018 |
Dec 19, 2018 |
| 6-K |
Report
|
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE |
Dec 18, 2018 |
Dec 18, 2018 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Dec 14, 2018 |
Dec 14, 2018 |
| 6-K |
Report
|
UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI |
Dec 7, 2018 |
Dec 7, 2018 |
| 6-K |
Report
|
DIVESTMENT OF RIGHTS TO COVIS COMPLETED |
Dec 6, 2018 |
Dec 6, 2018 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 4, 2018 |
Dec 4, 2018 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 3, 2018 |
Dec 3, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 3, 2018 |
Dec 3, 2018 |
| 6-K |
Report
|
GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED |
Dec 3, 2018 |
Dec 3, 2018 |
| 6-K |
Report
|
US FDA GRANTS FASENRA ODD FOR EGPA |
Nov 26, 2018 |
Nov 26, 2018 |
| 6-K |
Report
|
ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC |
Nov 16, 2018 |
Nov 16, 2018 |
| 6-K |
Report
|
ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI |
Nov 13, 2018 |
Nov 13, 2018 |
| 6-K |
Report
|
US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA |
Nov 13, 2018 |
Nov 13, 2018 |
| 6-K |
Report
|
FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR |
Nov 13, 2018 |
Nov 13, 2018 |
| 6-K |
Report
|
AZN: YEAR-TO-DATE AND Q3 2018 RESULTS |
Nov 8, 2018 |
Nov 8, 2018 |
| 6-K |
Report
|
DIVESTMENT OF RIGHTS TO COVIS PHARMA |
Nov 6, 2018 |
Nov 6, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2018 |
Nov 1, 2018 |
| 6-K |
Report
|
ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL |
Oct 31, 2018 |
Oct 31, 2018 |
| 6-K |
Report
|
GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO |
Oct 30, 2018 |
Oct 30, 2018 |
| 6-K |
Report
|
ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION |
Oct 23, 2018 |
Oct 23, 2018 |
| 6-K |
Report
|
LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER |
Oct 22, 2018 |
Oct 22, 2018 |
| 6-K |
Report
|
CHMP POSITIVE OPINION BEVESPI AEROSPHERE |
Oct 19, 2018 |
Oct 19, 2018 |
| 6-K |
Report
|
FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER |
Oct 16, 2018 |
Oct 16, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2018 |
Oct 1, 2018 |
| 6-K |
Report
|
ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED |
Oct 1, 2018 |
Oct 1, 2018 |
| 6-K |
Report
|
PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED |
Sep 28, 2018 |
Sep 28, 2018 |
| 6-K |
Report
|
OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC |
Sep 25, 2018 |
Sep 25, 2018 |
| 6-K |
Report
|
EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC |
Sep 24, 2018 |
Sep 24, 2018 |
| 6-K |
Report
|
FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 |
Sep 24, 2018 |
Sep 24, 2018 |
| 6-K |
Report
|
FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA |
Sep 14, 2018 |
Sep 14, 2018 |
| 6-K |
Report
|
TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION |
Sep 7, 2018 |
Sep 7, 2018 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Sep 6, 2018 |
Sep 6, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 4, 2018 |
Sep 4, 2018 |
| 6-K |
Report
|
ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE |
Aug 31, 2018 |
Aug 31, 2018 |
| 6-K |
Report
|
EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES |
Aug 30, 2018 |
Aug 30, 2018 |
| 6-K |
Report
|
ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE |
Aug 23, 2018 |
Aug 23, 2018 |
| 6-K |
Report
|
AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC |
Aug 21, 2018 |
Aug 21, 2018 |
| 6-K |
Report
|
FORM 6-K |
Aug 17, 2018 |
Aug 17, 2018 |
| 6-K |
Report
|
ASTRAZENECA PRICES A $3BN BOND ISSUE |
Aug 15, 2018 |
Aug 15, 2018 |
| 6-K |
Report
|
6-K |
Aug 10, 2018 |
Aug 10, 2018 |
| 6-K |
Report
|
EMA GRANTS OD FOR SELUMETINIB IN NF1 |
Aug 3, 2018 |
Aug 3, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2018 |
Aug 1, 2018 |
| 6-K |
Report
|
CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC |
Jul 27, 2018 |
Jul 27, 2018 |
| 6-K |
Report
| Data |
6-K |
Jul 26, 2018 |
Jul 26, 2018 |
| 6-K |
Report
|
ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE |
Jul 24, 2018 |
Jul 24, 2018 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 18, 2018 |
Jul 18, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 2, 2018 |
Jul 2, 2018 |
| 6-K |
Report
|
LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER |
Jul 2, 2018 |
Jul 2, 2018 |
| 6-K |
Report
|
IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC |
Jul 2, 2018 |
Jul 2, 2018 |
| 6-K |
Report
|
BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISE |
Jun 29, 2018 |
Jun 29, 2018 |
| 6-K |
Report
|
AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUEL |
Jun 28, 2018 |
Jun 28, 2018 |
| 6-K |
Report
|
LYNPARZA: SIGNIFICANT PFS 1ST-LINE OVARIAN CANCER |
Jun 27, 2018 |
Jun 27, 2018 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Jun 26, 2018 |
Jun 26, 2018 |
| 6-K |
Report
|
PUBLICATION OF A PROSPECTUS |
Jun 22, 2018 |
Jun 22, 2018 |
| 6-K |
Report
|
UPDATE: LANABECESTAT PHASE III ALZHEIMER'S TRIALS |
Jun 12, 2018 |
Jun 12, 2018 |
| 6-K |
Report
|
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC |
Jun 8, 2018 |
Jun 8, 2018 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Jun 8, 2018 |
Jun 8, 2018 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Jun 1, 2018 |
Jun 1, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2018 |
Jun 1, 2018 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Jun 1, 2018 |
Jun 1, 2018 |
| 6-K |
Report
|
UPDATE ON TERRANOVA PIII TRIAL FOR FASENRA IN COPD |
May 30, 2018 |
May 30, 2018 |
| 6-K |
Report
|
AZS IMFINZI: SIGNIFICANT OS IN STAGE III NSCLC |
May 25, 2018 |
May 25, 2018 |
| 6-K |
Report
|
AZ REGULATORY SUBMISSION IN JAPAN FOR FORXIGA |
May 21, 2018 |
May 21, 2018 |
| 6-K |
Report
|
US FDA APPROVES LOKELMA FOR ADULT HYPERKALAEMIA |
May 21, 2018 |
May 21, 2018 |
| 6-K |
Report
|
RESULT OF AGM |
May 18, 2018 |
May 18, 2018 |
| 6-K |
Report
|
AZN: Q1 2018 RESULTS |
May 18, 2018 |
May 18, 2018 |
| 6-K |
Report
|
ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPD |
May 11, 2018 |
May 11, 2018 |
| 6-K |
Report
|
EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER |
May 8, 2018 |
May 8, 2018 |
| 6-K |
Report
|
AZ AND LUYE PHARMA ENTER AGREEMENT FOR SEROQUEL |
May 7, 2018 |
May 7, 2018 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
May 4, 2018 |
May 4, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2018 |
May 1, 2018 |
| 6-K |
Report
|
AZ: POSITIVE CHMP FOR TAGRISSO FIRST-LINE NSCLC |
Apr 27, 2018 |
Apr 27, 2018 |
| 6-K |
Report
|
ASTRAZENECA:HIGH LEVEL RESULTS OF THE ARCTIC TRIAL |
Apr 24, 2018 |
Apr 24, 2018 |
| 6-K |
Report
|
FDA APPROVES TAGRISSO FOR 1ST-LINE USE IN NSCLC |
Apr 19, 2018 |
Apr 19, 2018 |
| 6-K |
Report
|
6-K |
Apr 13, 2018 |
Apr 13, 2018 |
| 6-K |
Report
|
NOTICE OF AGM |
Apr 13, 2018 |
Apr 13, 2018 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Apr 5, 2018 |
Apr 5, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 3, 2018 |
Apr 3, 2018 |
| 6-K |
Report
|
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA |
Apr 3, 2018 |
Apr 3, 2018 |
| 6-K |
Report
|
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU |
Apr 3, 2018 |
Apr 3, 2018 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 28, 2018 |
Mar 28, 2018 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 26, 2018 |
Mar 26, 2018 |
| 6-K |
Report
|
LOKELMA APPROVED IN THE EU |
Mar 22, 2018 |
Mar 22, 2018 |
| 6-K |
Report
|
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE |
Mar 12, 2018 |
Mar 12, 2018 |
| 6-K |
Report
|
FILING OF FORM 20-F WITH SEC |
Mar 7, 2018 |
Mar 7, 2018 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Mar 6, 2018 |
Mar 6, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2018 |
Mar 1, 2018 |
| 6-K |
Report
|
LYNPARZA CHMP FOR OVARIAN CANCER MAINTAINANCE |
Feb 23, 2018 |
Feb 23, 2018 |
| 6-K |
Report
|
ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLC |
Feb 20, 2018 |
Feb 20, 2018 |
| 6-K |
Report
|
SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS |
Feb 15, 2018 |
Feb 15, 2018 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 5, 2018 |
Feb 5, 2018 |
| 6-K |
Report
|
AZN: FULL-YEAR 2017 RESULTS |
Feb 2, 2018 |
Feb 2, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2018 |
Feb 1, 2018 |
| 6-K/A |
Report
|
AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD |
Jan 26, 2018 |
Jan 26, 2018 |
| 6-K |
Report
|
AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD |
Jan 26, 2018 |
Jan 26, 2018 |
| 6-K |
Report
|
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN |
Jan 19, 2018 |
Jan 19, 2018 |
| 6-K |
Report
|
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER |
Jan 19, 2018 |
Jan 19, 2018 |
| 6-K |
Report
|
FDA APPROVES LYNPARZA FOR METASTATIC BREAST CANCER |
Jan 12, 2018 |
Jan 12, 2018 |
| 6-K |
Report
|
ASTRAZENECA'S FASENRA APPROVED IN THE EU |
Jan 10, 2018 |
Jan 10, 2018 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2018 |
Jan 2, 2018 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 28, 2017 |
Dec 28, 2017 |
| 6-K |
Report
|
FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC |
Dec 18, 2017 |
Dec 18, 2017 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 15, 2017 |
Dec 15, 2017 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Dec 1, 2017 |
Dec 1, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2017 |
Dec 1, 2017 |
| 6-K |
Report
|
EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC |
Nov 28, 2017 |
Nov 28, 2017 |
| 6-K |
Report
|
AZ SUBMITS TAGRISSO IN JAPAN FOR 1ST-LINE NSCLC |
Nov 27, 2017 |
Nov 27, 2017 |
| 6-K |
Report
|
AZ FASENRA RECEIVES FDA APPROVAL FOR SEVERE ASTHMA |
Nov 15, 2017 |
Nov 14, 2017 |
| 6-K |
Report
|
BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA |
Nov 13, 2017 |
Nov 13, 2017 |
| 6-K |
Report
|
AZN: YEAR-TO-DATE AND Q3 2017 RESULTS ANNOUNCEMENT |
Nov 9, 2017 |
Nov 9, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2017 |
Nov 1, 2017 |
| 6-K |
Report
|
ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL |
Nov 1, 2017 |
Nov 1, 2017 |
| 6-K |
Report
|
ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA |
Nov 1, 2017 |
Nov 1, 2017 |
| 6-K |
Report
|
US FDA APPROVES ASTRAZENECA'S CALQUENCE FOR MCL |
Oct 31, 2017 |
Oct 31, 2017 |
| 6-K |
Report
|
US FDA APPROVES BYDUREON BCISE FOR TYPE-2 DIABETES |
Oct 23, 2017 |
Oct 23, 2017 |
| 6-K |
Report
|
AZ AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN |
Oct 23, 2017 |
Oct 23, 2017 |
| 6-K |
Report
|
FDA PRIORITY REVIEW FOR LYNPARZA IN BREAST CANCER |
Oct 18, 2017 |
Oct 18, 2017 |
| 6-K |
Report
|
FDA ACCEPTS SBLA FILE FOR IMFINZI; PRIORITY REVIEW |
Oct 17, 2017 |
Oct 17, 2017 |
| 6-K |
Report
|
FDA GRANTS TAGRISSO BTD FOR 1ST-LINE EGFR NSCLC |
Oct 10, 2017 |
Oct 10, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 2, 2017 |
Oct 2, 2017 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 26, 2017 |
Sep 26, 2017 |
| 6-K |
Report
|
ASPEN ACQUIRES REMAINING RIGHTS TO AZ ANAESTHETICS |
Sep 14, 2017 |
Sep 14, 2017 |
| 6-K |
Report
|
IMFINZI SUPERIOR PFS IN STAGE III LUNG CANCER |
Sep 11, 2017 |
Sep 11, 2017 |
| 6-K |
Report
|
TAGRISSO POTENTIAL STANDARD OF CARE IN LUNG CANCER |
Sep 11, 2017 |
Sep 11, 2017 |
| 6-K |
Report
|
CELGENE AND AZ UPDATE ON FUSION TRIAL PROGRAMME |
Sep 7, 2017 |
Sep 7, 2017 |
| 6-K |
Report
|
AZ DUAKLIR IMPROVES LUNG FUNCTION IN COPD PATIENTS |
Sep 7, 2017 |
Sep 7, 2017 |
| 6-K |
Report
|
AZ TEZEPELUMAB CUTS EXACERBATIONS IN SEVERE ASTHMA |
Sep 7, 2017 |
Sep 7, 2017 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Sep 5, 2017 |
Sep 5, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2017 |
Sep 1, 2017 |
| 6-K |
Report
|
LYNPARZA GETS BROAD FDA APPROVAL IN OVARIAN CANCER |
Aug 17, 2017 |
Aug 17, 2017 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Aug 16, 2017 |
Aug 16, 2017 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Aug 14, 2017 |
Aug 14, 2017 |
| 6-K |
Report
|
PUBLICATION OF A PROSPECTUS |
Aug 10, 2017 |
Aug 10, 2017 |
| 6-K |
Report
|
AZ ACALABRUTINIB SUBMISSION ACCEPTED BY US FDA |
Aug 2, 2017 |
Aug 2, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2017 |
Aug 1, 2017 |
| 6-K |
Report
|
BTD FOR AZS ACALABRUTINIB IN MANTLE CELL LYMPHOMA |
Aug 1, 2017 |
Aug 1, 2017 |
| 6-K |
Report
|
IMFINZI GRANTED BTD BY US FDA FOR STAGE III NSCLC |
Jul 31, 2017 |
Jul 31, 2017 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 28, 2017 |
Jul 28, 2017 |
| 6-K |
Report
|
TAGRISSO SIGNIFICANTLY IMPROVES FLAURA |
Jul 27, 2017 |
Jul 27, 2017 |
| 6-K |
Report
|
AZ REPORTS INITIAL RESULTS FROM MYSTIC LUNG TRIAL |
Jul 27, 2017 |
Jul 27, 2017 |
| 6-K |
Report
|
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL |
Jul 27, 2017 |
Jul 27, 2017 |
| 6-K |
Report
|
ASTRAZENECA PLC - H1 2017 RESULTS |
Jul 27, 2017 |
Jul 27, 2017 |
| 6-K |
Report
|
FASLODEX RECEIVES EU APPROVAL FOR 1L BREAST CANCER |
Jul 26, 2017 |
Jul 26, 2017 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 21, 2017 |
Jul 21, 2017 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 3, 2017 |
Jul 3, 2017 |
| 6-K |
Report
|
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI |
Jul 3, 2017 |
Jul 3, 2017 |
| 6-K |
Report
|
AZ COMPLETES ZOMIG DIVESTMENT WITH GRUNENTHAL |
Jul 3, 2017 |
Jul 3, 2017 |